US StockDetailed Quotes

Provided by Tiger Fintech (Singapore) Pte. Ltd.

Onestream Inc

21.29

+0.03000.14%

Volume:322.45K

Turnover:6.80M

Market Cap:3.75B

PE:-17.06

High:21.41

Open:21.31

Low:20.78

Close:21.26

Loading ...

Overview Company News Filings

Calidi Biotherapeutics and OS Therapies Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV

ACCESS Newswire

Lilly's Jaypirca (pirtobrutinib) recommended by CHMP for approval in the European Union for adults with relapsed or refractory chronic lymphocytic leukemia (CLL) previously treated with a BTK inhibitor

IMNN: Phase 3 Ovarian Cancer Trial to get Underway in Mar 2025…

Zacks Small Cap Research

ImmunityBio Receives FDA RMAT Designation for ANKTIVA® and CAR-NK for the Reversal of Lymphopenia in Patients Receiving Standard-of-Care Chemotherapy/Radiotherapy and in Treatment of Multiply Relapsed Locally Advanced or Metastatic Pancreatic Cancer

Arcellx Provides Fourth Quarter and Year-End 2024 Financial Results and Business Highlights

IMUNON Reports 2024 Financial Results and Provides Business Update Highlighting Significant Progress Towards the Initiation of a Pivotal Phase 3 Study

Agenus Reports Impact of Key Immuno-Oncology Data Presented at Leading Medical Conferences and Peer-Reviewed Publications

Revolution Medicines Reports Fourth Quarter and Full Year 2024 Financial Results and Update on Corporate Progress

Join OS Therapies’ Exclusive Live Investor Webinar and Q&A Session on February 27

MAIA Biotechnology Announces Design for Expansion of THIO-101 Phase 2 Trial in Advanced Non-Small Cell Lung Cancer

Geron Corporation Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Business Highlights

Immunocore reports fourth quarter and full year 2024 financial results and provides a business update

Camizestrant demonstrated highly statistically significant and clinically meaningful improvement in progression-free survival in 1st-line advanced HR-positive breast cancer with an emergent ESR1 tumor mutation in SERENA-6 Phase III trial

PDS Biotech Announces Circulating Tumor DNA Results for Versamune® HPV in IMMUNOCERV Trial Published in Clinical Cancer Research

Bristol Myers Cancer Drug Opdivo In Combination With Chemo Shows Improved Overall Survival In Certain Patients With Lung Cancer

Q4 2024 Hackett Group Inc Earnings Call

Thomson Reuters StreetEvents

Karyopharm Reports Fourth Quarter and Full Year 2024 Financial Results, Announces Update to Phase 3 XPORT-EC-042 Trial and Highlights Recent Company Progress

INAB: Continued Survival in INB-100 Trial

Zacks Small Cap Research

OneStream to Participate in Upcoming Investor Conference

Analysts Offer Insights on Technology Companies: Onestream, Inc. Class A (OS) and Super Micro Computer (SMCI)

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www-web.itiger.com/stock/OS/news?page=6"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"OS","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"OS\",,,,,undefined,":{"symbol":"OS","market":"US","secType":"STK","nameCN":"Onestream Inc","latestPrice":21.29,"timestamp":1746035785116,"preClose":21.26,"halted":0,"volume":322450,"delay":0,"floatShares":70199725,"shares":176023203,"eps":-1.247698,"marketStatus":"Trading","change":0.03,"latestTime":"04-30 13:56:26 EDT","open":21.31,"high":21.405,"low":20.775,"amount":6799525.39905,"amplitude":0.029633,"askPrice":21.3,"askSize":1,"bidPrice":21.26,"bidSize":323,"shortable":3,"etf":0,"ttmEps":-1.247698,"tradingStatus":2,"nextMarketStatus":{"tag":"Post-Mkt","tradingStatus":3,"beginTime":1746043200000},"marketStatusCode":2,"adr":0,"listingDate":1721793600000,"exchange":"NASDAQ","adjPreClose":21.26,"preHourTrading":{"tag":"盘前","latestPrice":21.25,"preClose":21.26,"latestTime":"09:29 EDT","volume":215,"amount":4575.579905,"timestamp":1746019799999},"postHourTrading":{"tag":"盘后","latestPrice":21.16,"preClose":21.26,"latestTime":"16:07 EDT","volume":7055,"amount":149947.28,"timestamp":1745957229565},"volumeRatio":0.647465,"impliedVol":0.9966,"impliedVolPercentile":0.9788},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"OS\",,,,,undefined,":{"symbol":"OS","floatShares":70199725,"roa":"-33.71%","roe":"-102.65%","lyrEps":-1.232998,"volumeRatio":0.647465,"shares":176023203,"dividePrice":0,"high":21.405,"amplitude":0.029633,"preClose":21.26,"low":20.775,"week52Low":16.6942,"pbRate":"9.70","psRate":"7.66","week52High":35.39,"institutionHeld":0,"latestPrice":21.29,"committee":0.993827,"eps":-1.247698,"divideRate":0,"volume":322450,"delay":0,"ttmEps":-1.247698,"open":21.31,"prevYearClose":28.52,"prevWeekClose":21.29,"prevMonthClose":21.34,"prevQuarterClose":21.34,"fiveDayClose":20.21,"twentyDayClose":22.68,"sixtyDayClose":28.585,"earningDate":1746633600000,"earningTime":"盘后"},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"OS\",pageSize:20,pageCount:6,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2514189327","title":"Calidi Biotherapeutics and OS Therapies Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV","url":"https://stock-news.laohu8.com/highlight/detail?id=2514189327","media":"ACCESS Newswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514189327?lang=en_us&edition=fundamental","pubTime":"2025-02-28 22:00","pubTimestamp":1740751200,"startTime":"0","endTime":"0","summary":"ORLANDO, FLORIDA / ACCESS Newswire / February 28, 2025 / RedChip Companies will air interviews with Calidi Biotherapeutics, Inc.  and OS Therapies Inc.  on the RedChip Small Stocks, Big Money show, a sponsored program on Bloomberg TV this Saturday, March 1, at 7 p.m. Eastern Time . Bloomberg TV is available in an estimated 73 million homes across the U.S.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/calidi-biotherapeutics-os-therapies-interviews-140000113.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4231","BK4144","TV","BK4097","TM","BK4555","BK4581","BK4561","BK4590","BK4099","ET","AIRI","BK4187","BK4588","OSTX","BK4100","BK4080","BK4585","03160","BK4139","BK4604","CLDI","OS","ADC"],"gpt_icon":0},{"id":"2514324925","title":"Lilly's Jaypirca (pirtobrutinib) recommended by CHMP for approval in the European Union for adults with relapsed or refractory chronic lymphocytic leukemia (CLL) previously treated with a BTK inhibitor","url":"https://stock-news.laohu8.com/highlight/detail?id=2514324925","media":"PR Newswire","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514324925?lang=en_us&edition=fundamental","pubTime":"2025-02-28 21:14","pubTimestamp":1740748440,"startTime":"0","endTime":"0","summary":"The positive opinion is based on results from the Phase 3 BRUIN CLL-321 trial, recently presented at the 2024 American Society of Hematology Annual Meeting. BRUIN CLL-321 is the first randomized Phase 3 study in CLL ever conducted exclusively in patients previously treated with a BTK inhibitor. The positive opinion is supported by data from the BRUIN CLL-321 clinical trial, the first randomized Phase 3 study in CLL ever conducted exclusively in patients previously treated with a BTK inhibitor. The study's primary endpoint of progression-free survival  was met at the prespecified time of final analysis , based on independent review committee  assessment, demonstrating pirtobrutinib was superior to investigator's choice of idelalisib plus rituximab  or bendamustine plus rituximab , both global standards of care.1 At an updated analysis , pirtobrutinib reduced therisk of disease progressionor death by 46% compared to IdelaR or BR, consistent with the primary analysis.PFS results were cons","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"yahoofinance","url":"https://finance.yahoo.com/news/lillys-jaypirca-pirtobrutinib-recommended-chmp-131400700.html","rn_cache_url":null,"customStyle":"img, svg { display: none !important; }","selectors":"article","filters":"","directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/lillys-jaypirca-pirtobrutinib-recommended-chmp-131400700.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["LU2237443465.HKD","LU1069344957.HKD","ORR","ASH","LU2237443622.USD","LU2237443382.USD","BK4226","LU0203201768.USD","LU0238689110.USD","BNTX","PRO","LU2461242641.AUD","LLY","LU1720051108.HKD","LU0640476718.USD","LU1974910355.USD","LU2602419157.SGD","LU0203202063.USD","BK4588","BK4109","LU1023059063.AUD","OS","LU2361045086.USD","LU0390134368.USD","LU0471298777.SGD","LU2063271972.USD","BK4516","BK4585","BK4599","LU2491050071.SGD","LU0882574139.USD","IE0009355771.USD","BK4533","BK4094","LU2237443978.SGD","LU1814569148.SGD","FL","CHMP","IE0002141913.USD","PFS","IE00BK4W5L77.USD","LU1267930730.SGD","LU1061106388.HKD","LU2211815571.USD","IE00BJT1NW94.SGD","LU2265009873.SGD","SG9999015986.USD","BR","SG9999001176.USD","LU0354030511.USD"],"gpt_icon":1},{"id":"2514375360","title":"IMNN: Phase 3 Ovarian Cancer Trial to get Underway in Mar 2025…","url":"https://stock-news.laohu8.com/highlight/detail?id=2514375360","media":"Zacks Small Cap Research","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514375360?lang=en_us&edition=fundamental","pubTime":"2025-02-28 18:07","pubTimestamp":1740737220,"startTime":"0","endTime":"0","summary":"Imunon, Inc.  is continuing preparations to conduct a Phase 3 clinical trial of its lead development compound, IMNN-001, in patients with advanced ovarian cancer. IMNN-001 is a DNA immunotherapeutic drug that consists of an interleukin -12 expressing plasmid that allows for the durable, local, and targeted expression of IL-12 in the peritoneum. IL-12 is a potent pro-inflammatory cytokine that mediates a number of important cellular processes, including T cell and natural killer cell activation , the production of interferon-gamma , and alteration of myeloid-derived suppressor cells in the tumor microenvironment . While shown to be effective in pre-clinical tumor models, IL-12 therapy initially showed underwhelming results in the clinic along with very high levels of toxicity when administered systemically. This is likely due to the fact that the direct targets of IL-12 are not circulating lymphocytes, but rather immune cells located within the tumor and lymph nodes. Thus, while systemi","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/imnn-phase-3-ovarian-cancer-100700685.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4161","LU0170899867.USD","BK4225","IE00BHPRN162.USD","BK4097","LU1363072403.SGD","CMC","BK4139","LU0053671581.USD","BK4006","CBD","BK4113","IE00BZ1G4Q59.USD","IE00BKVL7J92.USD","LU0054578231.USD","LU0267386448.USD","IMNN","BK4203","OS","ITT","HR","IE00B1BXHZ80.USD","LU0149725797.USD","LU0971096721.USD","LU0882574139.USD"],"gpt_icon":0},{"id":"2514368318","title":"ImmunityBio Receives FDA RMAT Designation for ANKTIVA® and CAR-NK for the Reversal of Lymphopenia in Patients Receiving Standard-of-Care Chemotherapy/Radiotherapy and in Treatment of Multiply Relapsed Locally Advanced or Metastatic Pancreatic Cancer","url":"https://stock-news.laohu8.com/highlight/detail?id=2514368318","media":"Business Wire","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514368318?lang=en_us&edition=fundamental","pubTime":"2025-02-28 08:10","pubTimestamp":1740701400,"startTime":"0","endTime":"0","summary":"Regenerative Medicine Advanced Therapy  designation follows clinical data of Absolute Lymphocyte Count  and significant Overall Survival  correlations in QUILT trials across multiple tumor types, including third line or greater metastatic pancreatic cancer, checkpoint relapsed NSCLC, and supportive data from healthy volunteers. The reversal of lymphopenia by ImmunityBio’s IL-15 superagonist is consistent with the mechanism of action of ANKTIVA demonstrating proliferation and activation of NK cells, CD4+ T cells, CD8+ T cells and memory T cells without upregulation of suppressive T regulatory cells and approved in the ANKTIVA label. However, chemotherapy and radiation has also caused a reduction in the very cells necessary to kill cancer cells. This reduction in the lymphocytes by our standard of care also inhibits the induction of T cell memory in the absence of CD4+, CD8+ T cells. A treatment for the reversal of these adverse events of lymphopenia, induced by current standard-of-care,","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/immunitybio-receives-fda-rmat-designation-001000822.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4097","BK4124","IE00B66KJ199.SGD","BK4230","BK4139","OS","CPI","AEIS","CAR","BK4157","SMP","IE00B7SZL793.SGD","BK4534","IE00B19Z4B17.USD","LU2265009873.SGD","IBRX","BK4135","IE0031619046.USD","LU1804176565.USD","BK4022","ALC","BCG","BK4198"],"gpt_icon":0},{"id":"2514358910","title":"Arcellx Provides Fourth Quarter and Year-End 2024 Financial Results and Business Highlights","url":"https://stock-news.laohu8.com/highlight/detail?id=2514358910","media":"Business Wire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514358910?lang=en_us&edition=fundamental","pubTime":"2025-02-28 05:00","pubTimestamp":1740690000,"startTime":"0","endTime":"0","summary":"-- Presented positive preliminary data at ASH 2024 from 86 patients enrolled in the Phase 2 pivotal iMMagine-1 study of anito-cel in patients with RRMM which demonstrated 97% ORR and 62% CR/sCR at a median follow-up of 9.5 months --. -- No delayed neurotoxicities observed with anito-cel, including no Parkinsonism, no cranial nerve palsies, and no Guillain-Barré syndrome in 155 patients dosed across the Phase 1 and iMMagine-1 studies as presented at ASH 2024 --. -- iMMagine-1 update planned for presentation mid-year 2025 --. -- Commercial launch of anito-cel in RRMM planned for 2026 --. -- Ended the quarter with $626M, reiterating cash runway into 2027 --. REDWOOD CITY, Calif., February 27, 2025----Arcellx, Inc. , a biotechnology company reimagining cell therapy through the development of innovative immunotherapies for patients with cancer and other incurable diseases, today reported business highlights and financial results for the fourth quarter and year ended December 31, 2024.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/arcellx-provides-fourth-quarter-end-210000599.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["ACLX","OS","BK4097","BK4139"],"gpt_icon":0},{"id":"2514596802","title":"IMUNON Reports 2024 Financial Results and Provides Business Update Highlighting Significant Progress Towards the Initiation of a Pivotal Phase 3 Study","url":"https://stock-news.laohu8.com/highlight/detail?id=2514596802","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514596802?lang=en_us&edition=fundamental","pubTime":"2025-02-27 21:05","pubTimestamp":1740661500,"startTime":"0","endTime":"0","summary":"IMNN-001 remains the first immunotherapy to achieve a meaningful overall survival benefit in advanced ovarian cancer Patient enrollment in Phase 3 pivotal trial of IMNN-001 scheduled to begin in Q1 20","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/02/27/3033835/0/en/IMUNON-Reports-2024-Financial-Results-and-Provides-Business-Update-Highlighting-Significant-Progress-Towards-the-Initiation-of-a-Pivotal-Phase-3-Study.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4006","BK4097","BK4203","IE00B1BXHZ80.USD","OS","BK4139","SITC","CMC","IE00BZ1G4Q59.USD","BK4225","LU0971096721.USD","PFS","BK4211","BK4080","LU0882574139.USD","LU1363072403.SGD","IMNN","LU0170899867.USD","IE00BHPRN162.USD","IE00BKVL7J92.USD","LU0149725797.USD","LU2065732104.USD","LU0267386448.USD","PRGS","HR","BK4195","BK4231"],"gpt_icon":0},{"id":"2514895520","title":"Agenus Reports Impact of Key Immuno-Oncology Data Presented at Leading Medical Conferences and Peer-Reviewed Publications","url":"https://stock-news.laohu8.com/highlight/detail?id=2514895520","media":"Business Wire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514895520?lang=en_us&edition=fundamental","pubTime":"2025-02-27 05:48","pubTimestamp":1740606480,"startTime":"0","endTime":"0","summary":"LEXINGTON, Mass., February 26, 2025----Agenus Inc. , a leader in immuno-oncology innovation, today highlights key scientific contributions in 2024-2025 that are shaping the future of cancer immunotherapy.Agenus is advancing a robust clinical pipeline targeting complementary mechanisms to fight cancer, including checkpoint inhibitors, immune activators, tumor microenvironment conditioning agents and cell therapies . Our most advanced antibody candidates, botensilimab  an Fc-enhanced CTLA-4 blocking antibody, and balstilimab , a novel, PD-1 inhibitor, are central to our efforts.BOT is currently being investigated as a monotherapy and in combination with widely used standard of care anti-PD-1, chemotherapy, and allogeneic cell therapy across multiple indications:. Dr. O’Day continues, \"By leveraging our deep expertise in immune activation, we are unlocking responses in tumors previously resistant to immunotherapy. The results are even more promising as we move from treatment refractory me","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/agenus-reports-impact-key-immuno-214800977.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["OS","LU0456854461.SGD","PFS","BK4211","LU0266512127.USD","R","CRC","BK4097","BK4232","BK4113","BK4139","BK4213","BK4022","AGEN","BAL","ORR","BK4195","MSS"],"gpt_icon":0},{"id":"2514867732","title":"Revolution Medicines Reports Fourth Quarter and Full Year 2024 Financial Results and Update on Corporate Progress","url":"https://stock-news.laohu8.com/highlight/detail?id=2514867732","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514867732?lang=en_us&edition=fundamental","pubTime":"2025-02-27 05:02","pubTimestamp":1740603720,"startTime":"0","endTime":"0","summary":"Company anticipates substantially completing enrollment this year in ongoing Phase 3 RASolute 302 trial of daraxonrasib in previously treated metastatic pancreatic cancer to enable expected data readout in 2026. Company is activating study sites for Phase 3 RASolve 301 trial of daraxonrasib in previously treated locally advanced or metastatic RAS mutant non-small cell lung cancer. Company anticipates initiating two additional registrational trials of daraxonrasib in earlier lines of treatment for pancreatic cancer in the second half of 2025. Revolution Medicines to hold webcast today at 4:30 p.m. Eastern Time. REDWOOD CITY, Calif., Feb. 26, 2025  -- Revolution Medicines, Inc. , a late-stage clinical oncology company developing targeted therapies for patients with RAS-addicted cancers, today announced its financial results for the quarter and full year ended December 31, 2024, and provided an update on corporate progress.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/revolution-medicines-reports-fourth-quarter-210200565.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4196","LU0124384867.USD","LU1720051108.HKD","RVMD","LU1854103824.USD","LU1720051017.SGD","BK4585","IE00B7SZLL34.SGD","BK4139","IE00BZ199S13.USD","LU0058720904.USD","BK4166","LU1059921491.USD","LU0868494617.USD","BK4211","LU0724618433.USD","LU1861214812.USD","MDCO","IE00BD6J9T35.USD","LU1861215975.USD","LU2357305700.SGD","CI","LU1861220033.SGD","LU2065732104.USD","BK4092","LU1861219969.SGD","LU2298322129.HKD","ON","PRGS","QD","RVMDW","BK4605","LU0289739699.SGD","LU1548497426.USD","LU1978683503.SGD","LU0348723411.USD","BK4195","BK4512","PFS","LU1854104046.USD","BK4563","NE","BK4503","IE00B19Z3B42.SGD","BK4097","IE0002270589.USD","IE00B19Z3581.USD","BK4588","LU2360107325.USD","OS"],"gpt_icon":0},{"id":"2514186726","title":"Join OS Therapies’ Exclusive Live Investor Webinar and Q&A Session on February 27","url":"https://stock-news.laohu8.com/highlight/detail?id=2514186726","media":"Business Wire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514186726?lang=en_us&edition=fundamental","pubTime":"2025-02-27 05:01","pubTimestamp":1740603660,"startTime":"0","endTime":"0","summary":"NEW YORK, February 26, 2025----OS Therapies  , a clinical-stage immunotherapy and Antibody Drug Conjugate biopharmaceutical company, is pleased to invite investors to a webinar on February 27, 2025, at 4:15 p.m. ET.The exclusive event, hosted by RedChip Companies, will feature OS Therapies’ Chairman and CEO, Paul Romness, and Chief Business Officer, Gerald Commissiong, who will provide an in-depth update on the Company’s rapidly advancing pipeline. OS Therapies is pioneering groundbreaking immunotherapies and antibody-drug conjugates  to address critical unmet needs in pediatric and young adult oncology, as well as a broad range of solid tumors. The Company’s lead candidate, OST-HER2, has demonstrated statistically significant improvements in 12-month event-free survival for recurrent, fully resected metastatic osteosarcoma, positioning it as a potential first-in-class treatment with accelerated FDA approval pathways. Additionally, OS Therapies’ proprietary Tunable Antibody Drug Conjug","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/join-os-therapies-exclusive-live-210100765.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["OS","BK4231","BK4080","BK4139","OSTX","ADC","BK4097"],"gpt_icon":0},{"id":"2514853387","title":"MAIA Biotechnology Announces Design for Expansion of THIO-101 Phase 2 Trial in Advanced Non-Small Cell Lung Cancer","url":"https://stock-news.laohu8.com/highlight/detail?id=2514853387","media":"Business Wire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514853387?lang=en_us&edition=fundamental","pubTime":"2025-02-26 21:47","pubTimestamp":1740577620,"startTime":"0","endTime":"0","summary":"Expansion study to enroll patients in the U.S. and select countries in Europe and Asia. CHICAGO, February 26, 2025----MAIA Biotechnology, Inc.,  , a clinical-stage biopharmaceutical company developing targeted immunotherapies for cancer, today announced the trial design for the expansion of its THIO-101 pivotal Phase 2 trial in non-small cell lung cancer . Following successful outcomes to date in THIO-101, the expansion of the study will assess overall response rates  in advanced NSCLC patients receiving third line  therapy who were resistant to previous checkpoint inhibitor treatments  and chemotherapy.MAIA recently announced an amended clinical supply agreement with Regeneron to include the expansion portion of THIO-101. Under terms of the amended agreement, MAIA continues to sponsor THIO-101 and Regeneron will provide Libtayo for the treatment of all patients including the additional patients in the expansion and potentially, the registration studies.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/maia-biotechnology-announces-design-expansion-134700870.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4588","MAIA","LU0053666078.USD","IE0002270589.USD","IE00B66KJ199.SGD","BK4107","CI","IE00B7SZL793.SGD","IE00B19Z4B17.USD","L","LU0868494617.USD","BK4097","BK4139","BK4585","LU1059921491.USD","IE00B19Z3B42.SGD","BK4157","LU1261432733.SGD","LU0058720904.USD","CPI","IE00BSNM7G36.USD","OS","BK4196","LU0289739699.SGD","ORR","AEIS","IE0031619046.USD","IE00B19Z3581.USD"],"gpt_icon":0},{"id":"2514483443","title":"Geron Corporation Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Business Highlights","url":"https://stock-news.laohu8.com/highlight/detail?id=2514483443","media":"Business Wire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514483443?lang=en_us&edition=fundamental","pubTime":"2025-02-26 20:30","pubTimestamp":1740573000,"startTime":"0","endTime":"0","summary":"Achieved $47.5 million in RYTELO  net product revenue in Q4 2024 and $76.5 million since commercial launch at the end of June 2024, following FDA approval. Expect to reach profitability without additional financing if current internal sales and operating expenses expectations are met. FOSTER CITY, Calif., February 26, 2025----Geron Corporation , a commercial-stage biopharmaceutical company aiming to change lives by changing the course of blood cancer, today reported financial results for the fourth quarter and full year 2024 and recent business highlights.Continued execution on U.S. commercial launch, with net product revenue for RYTELO  of $47.5 million in the fourth quarter of 2024 and $76.5 million since launch at the end of June 2024, following approval by the U.S. Food and Drug Administration .Presented new data at the 66th American Society for Hematology  Annual Meeting in December 2024, including analyses of IMerge Phase 3 data suggesting clinical activity o","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/geron-corporation-reports-fourth-quarter-123000150.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4109","ASH","GERN","OS","BK4097","BK4087","CHMP","BK4139","LU2463526074.USD"],"gpt_icon":0},{"id":"2514983992","title":"Immunocore reports fourth quarter and full year 2024 financial results and provides a business update","url":"https://stock-news.laohu8.com/highlight/detail?id=2514983992","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514983992?lang=en_us&edition=fundamental","pubTime":"2025-02-26 20:00","pubTimestamp":1740571200,"startTime":"0","endTime":"0","summary":"KIMMTRAK  Q4 net sales of $84.1 million and $310.0 million for full year 2024; continued growth expected in 2025. Executing on KIMMTRAK lifecycle management with two Phase 3 trials  in additional melanoma indications. Advancing PRAME portfolio – first patient randomized in Phase 3 PRISM-MEL-301; enrollment continues in Phase 1/2 trial of brenetafusp combinations in ovarian cancer and NSCLC; first patient dosed in Phase 1 trial of IMC-P115C . First patient dosed in Phase 1/2 trial of IMC-R117C  in colorectal and other gastrointestinal cancers. CTA/IND on track for IMC-S118AI  in 2H 2025 and for IMC-U120AI, our first non-HLA-restricted candidate initially for atopic dermatitis, in 2026. Cash, cash equivalents and marketable securities of $820.4 million as of December 31, 2024. “In 2024, we continued to grow KIMMTRAK sales, execute on our KIMMTRAK lifecycle management program, advance our deep clinical pipeline, and expand into autoimmune diseases, supported by a strong cash position and ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/immunocore-reports-fourth-quarter-full-120000489.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["LU1093756168.USD","BK4195","BK4533","ALT","IE0031619046.USD","LU1093756325.SGD","BK4007","BK4567","BK4121","CRS","IE00BFXG0V08.USD","LU2413666426.HKD","ORR","BK4505","BK4585","BK4588","BK4006","BK4139","BK4548","LU2065731478.USD","BK4207","LU0347712357.USD","PFS","OS","BK4147","CTA","BK4211","LU1721428933.USD","BK4599","BK4097","LU2413666699.HKD","MTD","ATOM","LU1878469433.USD","IE00BYQQ9H92.USD","IMCR","PROC","IE00B66KJ199.SGD","IE00B7SZL793.SGD","CM","IE00B19Z4B17.USD"],"gpt_icon":0},{"id":"2514831987","title":"Camizestrant demonstrated highly statistically significant and clinically meaningful improvement in progression-free survival in 1st-line advanced HR-positive breast cancer with an emergent ESR1 tumor mutation in SERENA-6 Phase III trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2514831987","media":"Business Wire","labels":["dataReport","merge"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514831987?lang=en_us&edition=fundamental","pubTime":"2025-02-26 20:00","pubTimestamp":1740571200,"startTime":"0","endTime":"0","summary":"First and only next-generation oral SERD and complete ER antagonist to demonstrate 1st-line benefit in combination with widely approved CDK4/6 inhibitors. The key secondary endpoints of time to second disease progression  and overall survival  were immature at the time of this interim analysis. However, the camizestrant combination demonstrated a trend toward improvement in PFS2. The trial will continue as planned to further assess key secondary endpoints.Susan Galbraith, Executive Vice President, Oncology Hematology R&D, AstraZeneca, said: \"These impressive results demonstrate the versatility of camizestrant in combination with all the widely approved CDK4/6 inhibitors to provide a well-tolerated new potential treatment option in the first-line setting for the one in three patients with HR-positive, HER2-negative advanced breast cancer whose tumors develop ESR1 mutations during","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/camizestrant-demonstrated-highly-statistically-significant-120000062.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"dataReport,merge","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4097","LU2456880835.USD","LU0109394709.USD","BK4225","BK4585","PFS","BK4195","LU2236285917.USD","LU0320765992.SGD","BK4203","BK4588","III","LU0889565916.HKD","LU2462157665.USD","HR","BK4211","AZN","OS","BK4568","BK4007","BK4134","LU2417539215.USD","LU1829250122.USD"],"gpt_icon":0},{"id":"2513726307","title":"PDS Biotech Announces Circulating Tumor DNA Results for Versamune® HPV in IMMUNOCERV Trial Published in Clinical Cancer Research","url":"https://stock-news.laohu8.com/highlight/detail?id=2513726307","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2513726307?lang=en_us&edition=fundamental","pubTime":"2025-02-24 21:00","pubTimestamp":1740402000,"startTime":"0","endTime":"0","summary":"Data confirms Versamune HPV has potential as a broadly effective treatment of HPV16-associated cancers –Initiation of Phase 3 trial in HPV16-positive HNSCC planned for Q1 2025. Versamune HPV + CRT was associated with greater and earlier clearance of blood-circulating HPV16-positive cancer cells  vs. CRT alone. 100% of patients with locally advanced HPV16 cervical cancer treated with Versamune HPV + CRT had no detectable HPV16 ctDNA at 3-4 months vs. 50% of patients on standard-of-care CRT. Undetectable HPV ctDNA at 3-4 months was associated with improved 2-year recurrence-free survival  of 93% vs only 30% in patients with detectable HPV ctDNA. A total of 66 patients with locally advanced cervical cancer were enrolled, with 49 receiving CRT and 17 receiving a combination of CRT and Versamune HPV. Patient blood was collected at baseline, weeks 1, 3, and 5 of CRT, and 3 to 4 months after CRT to measure HPV ctDNA. MRI was performed at baseline and before brachytherapy to determine tumor sh","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/pds-biotech-announces-circulating-tumor-130000736.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4080","OS","BK4109","CRT","BK4213","BK4092","DNA","BK4231","PDS","ADC","BK4139","BK4097","PDSB"],"gpt_icon":0},{"id":"2512432823","title":"Bristol Myers Cancer Drug Opdivo In Combination With Chemo Shows Improved Overall Survival In Certain Patients With Lung Cancer","url":"https://stock-news.laohu8.com/highlight/detail?id=2512432823","media":"Benzinga","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2512432823?lang=en_us&edition=fundamental","pubTime":"2025-02-20 05:14","pubTimestamp":1739999669,"startTime":"0","endTime":"0","summary":"On Wednesday, Bristol Myers Squibb& Co  announced the final analysis of overall survival  from the Phase 3 CheckMate -816 study, which evaluatedOpdivo  in combination with platinum-doublet chemotherapy as a neoadjuvant treatment for adult patients with resectable non-small cell lung cancer .Also Read: Trump’s Tax Cut Could Add $4.6 Trillion To Deficit, With $48 Billion Tax Relief For Top 100 Firms: Robert Reich. The results showed a statistically significant and clinically meaningful improvement in overall survival, a key secondary endpoint, compared to neoadjuvant chemotherapy alone.The results build on the previously reported primary endpoints of event-free survival  and pathological complete response , which also met statistical significance.The safety profile ofOpdivoin combination with chemotherapy was consistent with previously reported studies, with no new safety signals observed.Price Action: BMY stock closed higher by 1.01% to $54.98 on Wednesday.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/bristol-myers-cancer-drug-opdivo-211429682.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["ALK","LU1868836757.USD","BK4559","LU1989771016.USD","LU0306806265.USD","IE00BJT1NW94.SGD","LU1032466523.USD","LU1670710588.SGD","LU0061475181.USD","BMY","IE0009355771.USD","LU1868836591.USD","LU0321505439.SGD","LU0225284248.USD","LU0985481810.HKD","LU1868836914.USD","BK4500","LU0225771236.USD","LU1670710661.SGD","IE0002141913.USD","LU1291159041.SGD","LU1718418525.SGD","BK4126","OS","IE00BSNM7G36.USD","LU1670711040.USD","BK4585","LU2242652126.USD","LU2360032135.SGD","ORR","LU2125154778.USD","LU1093756168.USD","IE00BJJMRZ35.SGD","LU2125154935.USD","LU1670711123.USD","LU2133065610.SGD","LU1074936037.SGD","LU1261432733.SGD","LU0306807586.USD","LU1585245621.USD","MYE","LU0868494617.USD","LU0096364046.USD","LU1093756325.SGD","LU1323610961.USD","LU1868837300.USD","LU1430594728.SGD","LU0321505868.SGD","IE00BFTCPJ56.SGD","BK4008"],"gpt_icon":0},{"id":"2512482419","title":"Q4 2024 Hackett Group Inc Earnings Call","url":"https://stock-news.laohu8.com/highlight/detail?id=2512482419","media":"Thomson Reuters StreetEvents","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2512482419?lang=en_us&edition=fundamental","pubTime":"2025-02-20 00:52","pubTimestamp":1739983960,"startTime":"0","endTime":"0","summary":"Robert Ramirez; Chief Financial Officer, Executive Vice President - Finance; Hackett Group Inc. Ted Fernandez; Chairman of the Board, Chief Executive Officer; Hackett Group Inc. Thank you, Rob, and welcome, everyone, to our fourth quarter earnings call. As we normally do, I'll open the call with some overview comments on the quarter. I will then turn it back over to Rob to comment on detailed operating results, cash flow and guidance. We will then review our market and strategy-related comments, after which we will open it up to Q&A. This afternoon, we reported total revenues of $79.2 million and adjusted earnings per share of $0.47, both exceeding our quarterly guidance. Our results were driven by the overperformance of our SAP segment and the strong performance of our GSBT segment, which continued to see increased revenue growth from our GenAI engagements. GenAI revenues have a higher margin than our traditional consulting and implementation revenues and are driven by highly differen","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/q4-2024-hackett-group-inc-165240034.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["HCKT","OS","ORCL"],"gpt_icon":0},{"id":"2512104071","title":"Karyopharm Reports Fourth Quarter and Full Year 2024 Financial Results, Announces Update to Phase 3 XPORT-EC-042 Trial and Highlights Recent Company Progress","url":"https://stock-news.laohu8.com/highlight/detail?id=2512104071","media":"PR Newswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2512104071?lang=en_us&edition=fundamental","pubTime":"2025-02-19 20:30","pubTimestamp":1739968200,"startTime":"0","endTime":"0","summary":"– Total Revenue of $145 Million and U.S. XPOVIO  Net Product Revenue of $113 Million for Full Year 2024 –。–Top-Line Data Readout from Phase 3 SENTRY Trial Evaluating Selinexor in Combination with Ruxolitinib in Patients with JAKi-Nave Myelofibrosis Anticipated in 2H 2025; Company on Track to Complete Enrollment in 1H 2025 –。–Company Announces Update to Phase 3 XPORT-EC-042 Trial of Selinexor as Maintenance Therapy in Advanced or Recurrent TP53 Wild-Type Endometrial Cancer. Following Dialogue with the FDA Regarding the Evolving Treatment Landscape, Trial to Focus Enrollment on Patients with Either pMMR Tumors or Patients with dMMR Tumors that are Medically Ineligible for Checkpoint Inhibitors. Increasing Sample Size to 276; Top-Line Data Now Expected in Mid-2026 –。– Company Provides Full-Year 2025 Total Revenue Guidance of $140 Million to $155 Million, Including U.S. XPOVIO Net Product Revenue Guidance of $115 Million to $130 Million –","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"yahoofinance","url":"https://finance.yahoo.com/news/karyopharm-reports-fourth-quarter-full-123000326.html","rn_cache_url":null,"customStyle":"img, svg { display: none !important; }","selectors":"article","filters":"","directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/karyopharm-reports-fourth-quarter-full-123000326.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4097","BK4161","OS","PRGS","LU0054578231.USD","EC","ITT","PFS","LU2065732104.USD","BK4195","LU0053671581.USD","BK4139","BK4211","KPTI","BK4201"],"gpt_icon":0},{"id":"2512484426","title":"INAB: Continued Survival in INB-100 Trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2512484426","media":"Zacks Small Cap Research","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2512484426?lang=en_us&edition=fundamental","pubTime":"2025-02-19 19:11","pubTimestamp":1739963460,"startTime":"0","endTime":"0","summary":"IN8bio, Inc  updates survival data for its INB-100 trial in a February 11thpress release in preparation for presentation of data at the Transplantation & Cellular Therapy  Meetings in Hawaii last week. Data for patients enrolled in the trial were updated from early August 2024 to January 17th, 2025. All of the acute myeloid leukemia  patients across both original and expansion cohorts remain in complete remission , with a median follow-up of 20.1 months. All of the AML patients achieved one year of progression free survival  and overall survival . Since our last update, IN8bio has participated in multiple investor and scientific conferences, including Biotech Showcase, Noble’s Emerging Growth Conference, the American Society of Hematology Annual Meeting and the TCT meetings.The results are remarkable as real-world survival rates for AML patients following hematopoietic stem cell transplantation  are lower. For example, the Center for International Blood and Marrow Transplant Research  ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/inab-continued-survival-inb-100-111100490.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["INAB","BK4161","CRS","HSCT","PFS","INB","LU2065731478.USD","BK4539","BK4195","IE00B7SZL793.SGD","BK4139","CR","BK4211","BK4006","IE00B19Z4B17.USD","OS","BK4097","IE00B66KJ199.SGD","IE0031619046.USD"],"gpt_icon":0},{"id":"2512895116","title":"OneStream to Participate in Upcoming Investor Conference","url":"https://stock-news.laohu8.com/highlight/detail?id=2512895116","media":"PR Newswire","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2512895116?lang=en_us&edition=fundamental","pubTime":"2025-02-19 07:00","pubTimestamp":1739919600,"startTime":"0","endTime":"0","summary":"BIRMINGHAM, Mich., Feb. 18, 2025 /PRNewswire/ -- OneStream, Inc. , the leading enterprise Finance management platform that modernizes the Office of the CFO by unifying core finance and operational functions -- including financial close, consolidation, reporting, planning and forecasting -- today announced that it will be presenting at the Morgan Stanley Technology, Media & Telecom Conference on Tuesday, March 4, at 11:30 a.m. ET / 8:30 a.m. PT in San Francisco, CA.OneStream is how today's Finance teams can go beyond just reporting on the past and Take Finance Further by steering the business to the future. It's the leading enterprise finance platform that unifies financial and operational data, embeds AI for better decisions and productivity, and empowers the CFO to become a critical driver of business strategy and execution.We deliver a comprehensive cloud-based platform to modernize the Office of the CFO. Our Digital Finance Cloud unifies core financial and broader operational data a","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"yahoofinance","url":"https://finance.yahoo.com/news/onestream-participate-upcoming-investor-conference-230000607.html","rn_cache_url":null,"customStyle":"img, svg { display: none !important; }","selectors":"article","filters":"","directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/onestream-participate-upcoming-investor-conference-230000607.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["LU2271345857.HKD","LU1989772923.USD","LU0912757837.SGD","LU0158827781.USD","LU1363072403.SGD","LU1989772840.SGD","LU2357305700.SGD","IE00BKVL7J92.USD","LU2111349929.HKD","LU0098860793.USD","BK4588","LU0106831901.USD","OS","BK4097","BK4504","LU2028103732.USD","LU2347655156.SGD","LU0795875086.SGD","LU1732799900.SGD","LU1162221912.USD","LU2023251221.USD","LU0971096721.USD","BK4581","LU1732800096.USD","LU0006306889.USD","IE00BZ1G4Q59.USD","LU1074936037.SGD","LU1720051017.SGD","BK4585","LU0795875169.SGD","BK4127","LU1548497426.USD","BK4516","LU0314104364.USD","LU1668664300.SGD","LU2089283258.USD","LU0158827948.USD","LU0267386448.USD","LU0320765646.SGD","LU1720051108.HKD","BK4534","LU0106261372.USD","LU2089284900.SGD","LU0225283273.USD","LU2133065610.SGD"],"gpt_icon":0},{"id":"2512940315","title":"Analysts Offer Insights on Technology Companies: Onestream, Inc. Class A (OS) and Super Micro Computer (SMCI)","url":"https://stock-news.laohu8.com/highlight/detail?id=2512940315","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2512940315?lang=en_us&edition=fundamental","pubTime":"2025-02-17 21:32","pubTimestamp":1739799149,"startTime":"0","endTime":"0","summary":"Analysts have been eager to weigh in on the Technology sector with new ratings on Onestream, Inc. Class A (OS – Research Report) and Super Micro Co...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-technology-companies-onestream-inc-class-a-os-and-super-micro-computer-smci?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-technology-companies-onestream-inc-class-a-os-and-super-micro-computer-smci?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4097","LU1861215975.USD","LU1861220033.SGD","OS","BK4170","SMCI","LU0053671581.USD","BK4585","BK4588","BK4543"],"gpt_icon":0}],"pageSize":20,"totalPage":10,"pageCount":6,"totalSize":200,"code":"91000000","status":"200"}],"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/OS\",params:#limit:5,,,undefined,":[{"date":"2025-05-08","symbol":"OS","type":"earning","reportTimeType":"post","market":"US","fiscalQuarterEnding":"2025/03","expectedEps":-0.06,"defaultRemindTime":1746734400000,"name":null,"time":"Post Market","dateTimestamp":1746676800000,"actualEps":null},{"market":"US","date":"2025-02-11","symbol":"OS","fiscalQuarterEnding":"2024/12","expectedEps":0.02,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1739250000000,"reportTimeType":"post","actualEps":0.07},{"market":"US","date":"2024-11-07","symbol":"OS","fiscalQuarterEnding":"2024/09","expectedEps":0,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1730955600000,"reportTimeType":"post","actualEps":-1.06},{"market":"US","date":"2024-09-03","symbol":"OS","fiscalQuarterEnding":"2024/06","expectedEps":-0.11,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1725336000000,"reportTimeType":"post","actualEps":null}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"OS\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"OS\",market:\"US\",delay:false,,,undefined,":{"strongBuy":0.3333,"buy":0.5556,"hold":0.1111,"sell":0,"strongSell":0,"meanLabel":"BUY","meanPercent":0.5556,"analysts":18,"updateTime":1742356800000},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/OS\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"OS","date":"2025-04-29","current":-17.178873,"percent":0.901639,"low":-1655.61542,"twenty":-1413.843009,"median":-27.388849,"eighty":-18.7477,"high":-14.493656,"avg":-426.817199,"sd":615.425447,"marketCap":3714089583},"quantilePoints":[{"date":"2024-08-02","current":-402.058638,"twenty":-402.058638,"median":-402.058638,"eighty":-402.058638,"marketCap":4348264172},{"date":"2024-08-09","current":-394.529993,"twenty":-398.004752,"median":-394.602383,"eighty":-391.489578,"marketCap":4266841869},{"date":"2024-08-16","current":-420.156344,"twenty":-402.058638,"median":-395.977809,"eighty":-394.529993,"marketCap":4543990864},{"date":"2024-08-23","current":-418.563746,"twenty":-420.156344,"median":-400.248867,"eighty":-394.674774,"marketCap":4526766915},{"date":"2024-08-30","current":-439.701867,"twenty":-427.829772,"median":-415.668113,"eighty":-395.977809,"marketCap":4755375690},{"date":"2024-09-06","current":-1412.285699,"twenty":-434.093948,"median":-420.156344,"eighty":-395.977809,"marketCap":4652069092},{"date":"2024-09-13","current":-1421.532228,"twenty":-630.517125,"median":-426.381956,"eighty":-397.599363,"marketCap":4682527160},{"date":"2024-09-20","current":-1491.611188,"twenty":-1406.835113,"median":-428.55368,"eighty":-398.352228,"marketCap":4913367253},{"date":"2024-09-27","current":-1641.015636,"twenty":-1479.542034,"median":-435.672004,"eighty":-401.33473,"marketCap":5405505506},{"date":"2024-10-04","current":-1582.129844,"twenty":-1582.616503,"median":-445.348351,"eighty":-408.313205,"marketCap":5211535706},{"date":"2024-10-11","current":-1384.546111,"twenty":-1557.991535,"median":-1361.673117,"eighty":-414.50986,"marketCap":4560694889},{"date":"2024-10-18","current":-1422.505547,"twenty":-1506.405635,"median":-1387.466067,"eighty":-417.984619,"marketCap":4685733272},{"date":"2024-10-25","current":-1513.510863,"twenty":-1501.052381,"median":-1410.582391,"eighty":-419.837824,"marketCap":4985504782},{"date":"2024-10-31","current":-1488.204572,"twenty":-1545.825049,"median":-1419.58559,"eighty":-422.588676,"marketCap":4902145859},{"date":"2024-11-08","current":-29.444986,"twenty":-1544.267739,"median":-1421.532228,"eighty":-422.588676,"marketCap":5359016876},{"date":"2024-11-15","current":-29.547337,"twenty":-1525.190689,"median":-1414.232336,"eighty":-406.749563,"marketCap":5377644907},{"date":"2024-11-22","current":-27.361909,"twenty":-1504.167001,"median":-1405.472467,"eighty":-395.977809,"marketCap":4979894851},{"date":"2024-11-29","current":-26.339693,"twenty":-1496.769778,"median":-1384.546111,"eighty":-392.705744,"marketCap":4793850470},{"date":"2024-12-06","current":-28.33551,"twenty":-1493.655158,"median":-903.058146,"eighty":-29.829328,"marketCap":5157091209},{"date":"2024-12-13","current":-28.454992,"twenty":-1490.248542,"median":-439.701867,"eighty":-28.749622,"marketCap":5178836972},{"date":"2024-12-20","current":-27.223413,"twenty":-1484.895288,"median":-431.521704,"eighty":-28.258307,"marketCap":4954688343},{"date":"2024-12-27","current":-27.048786,"twenty":-1479.834029,"median":-428.191726,"eighty":-28.004145,"marketCap":4922906075},{"date":"2025-01-03","current":-25.973452,"twenty":-1479.444702,"median":-426.381956,"eighty":-27.732022,"marketCap":4727194212},{"date":"2025-01-10","current":-24.227183,"twenty":-1479.444702,"median":-422.183287,"eighty":-27.252823,"marketCap":4409371530},{"date":"2025-01-17","current":-26.460569,"twenty":-1468.54353,"median":-415.668113,"eighty":-26.869269,"marketCap":4815850013},{"date":"2025-01-24","current":-27.894348,"twenty":-1465.818237,"median":-402.058638,"eighty":-26.861301,"marketCap":5076799163},{"date":"2025-01-31","current":-27.407231,"twenty":-1462.314289,"median":-396.991281,"eighty":-26.925021,"marketCap":4988143362},{"date":"2025-02-07","current":-27.09474,"twenty":-1459.102337,"median":-394.674774,"eighty":-26.925021,"marketCap":4931269830},{"date":"2025-02-14","current":-19.646244,"twenty":-1457.642359,"median":-390.041762,"eighty":-26.782239,"marketCap":4247537655},{"date":"2025-02-21","current":-19.437413,"twenty":-1455.695721,"median":-30.305187,"eighty":-26.72172,"marketCap":4202388031},{"date":"2025-02-28","current":-18.385222,"twenty":-1452.094441,"median":-29.520901,"eighty":-26.562732,"marketCap":3974903390},{"date":"2025-03-07","current":-18.486889,"twenty":-1446.059864,"median":-28.777108,"eighty":-26.339693,"marketCap":3996883783},{"date":"2025-03-14","current":-16.449855,"twenty":-1440.122619,"median":-28.454992,"eighty":-26.179328,"marketCap":3556475076},{"date":"2025-03-21","current":-17.921046,"twenty":-1437.981318,"median":-28.198548,"eighty":-25.317223,"marketCap":3874548031},{"date":"2025-03-28","current":-18.76981,"twenty":-1430.38943,"median":-27.986257,"eighty":-24.094834,"marketCap":4058051659},{"date":"2025-04-04","current":-16.296269,"twenty":-1422.116219,"median":-27.889753,"eighty":-20.198845,"marketCap":3523269657},{"date":"2025-04-11","current":-15.87621,"twenty":-1419.974918,"median":-27.820821,"eighty":-19.520945,"marketCap":3432452458},{"date":"2025-04-17","current":-15.802935,"twenty":-1417.346957,"median":-27.682957,"eighty":-19.180725,"marketCap":3416610370},{"date":"2025-04-25","current":-17.317281,"twenty":-1415.400319,"median":-27.425612,"eighty":-18.846182,"marketCap":3744013527},{"date":"2025-04-29","current":-17.178873,"twenty":-1413.843009,"median":-27.388849,"eighty":-18.7477,"marketCap":3714089583}],"updateTime":1746033087091}}}